Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aetna issues new ESA policy

Private insurer Aetna issued a new policy regarding its coverage of erythropoiesis-stimulating agents (ESAs) that is less restrictive than

Read the full 196 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE